This healthtech startup isn’t trying to be Theranos – it’s aiming to be one step ahead, with verifiable AI that’s already helping doctors and patients.
In an era where ostentatious promises about revolutionising blood diagnostics have burned many in the past, one startup is determined to do it differently with transparency, rigour, and actual market traction.
Meet BloodGPT, a healthtech company founded in Cyprus building what it calls the “ChatGPT for blood.” The platform already works and is turning complex lab reports into clear, actionable insights in under two minutes, with over 500 paying B2C subscribers already using it.
Now, the startup is getting ready to unveil its B2B version for hospitals, clinics, and labs at the upcoming event in Orlando, Florida, next week.
From a neighbourly idea to a medical AI startup
The origin story of BloodGPT is refreshingly human. Nikita Udovichenko, a seasoned biochemist and sports nutrition consultant, had long seen how patients struggled to understand their blood work. “People were frustrated. They didn’t know what the numbers meant,” he tells TFN.
Enter Vasilii Lazuka, his neighbour and a serial AI entrepreneur. “When I first heard the idea, I thought: I can build this in two days,” Lazuka laughs. “Of course, once we started testing with more complex data – 50+ parameters, multiple time points – it became clear we needed a much more sophisticated architecture.”
Together, the pair built BloodGPT with a bold vision: to create a tool that works for patients and doctors alike – a stark contrast to many AI products that ignore clinical realities.
Why BloodGPT is one step ahead
Unlike consumer-grade health chatbots that simply wrap a generic LLM like ChatGPT, BloodGPT is built with multi-agent AI architecture designed specifically for medical data.
“For us, 5% error is unacceptable in healthcare,” says Lazuka. “Even 0.5% could cause real harm in clinical use. That’s why we engineered it from scratch with full traceability and validation.”
Key features include:
- Instant analysis of any blood test across 98 languages and different lab formats.
- Trend analysis across multiple tests and timepoints.
- Clinicians support tools with explainable AI and the ability for doctors to review, edit, and approve recommendations.
- Integration-ready architecture, fully compatible with major systems like InterSystems, which serves 150+ countries.
Why it matters now
Clinician burnout is surging globally with nearly half of US physicians reporting symptoms of burnout, according to Stanford. Reviewing labs is a major time sink.
BloodGPT reduces that from 4-7 hours per week to 30 minutes or less – freeing doctors to focus on higher-value patient care.
For patients, the system turns cryptic PDFs into personalised dashboards with clear explanations and trend visualisations, making preventive health far more accessible.
A real product, already in use
BloodGPT co-founders Vasilii Lazuka, co-founder & CEO, Nikita Udovichenko, co-founder, and Nata Savaścienka, co-founder, Head of Product tell TFN they already have 500+ consumer subscribers, with overwhelmingly positive feedback. “People love it because it speaks their language,” says Jonathan Kron, a strategic advisor to the company. “And for doctors, it saves significant time, while keeping them in full control.”
The B2B version is also attracting interest from clinics, hospitals, and labs. “We’re seeing demand across the board, from doctors and small practices, to large hospital systems, to laboratories that want to offer more engaging reports to patients,” says Kron.
A particularly exciting potential use case: pharma partnerships. “Subscription-based supplement companies could integrate BloodGPT to provide real-time feedback on how their products are affecting blood markers,” Lazuka explains. “Imagine seeing your health trends improve – backed by your actual blood data.”
Addressing AI skepticism in healthcare
Of course, introducing AI into clinical decision making isn’t without challenges.
“There’s resistance,” admits Kron. “And rightly so, clinicians need to trust what they’re using. That’s why we built BloodGPT with full transparency. Doctors can see, edit, and override everything. It’s a support tool not a replacement.”
BloodGPT is also fully aware of regulatory hurdles. While the B2C product is already live, the B2B clinical version will go through proper medical device certification in Europe, UK, and the US. “We’re committed to doing this right,” says Udovichenko.
Funding and the road ahead
So far, BloodGPT has raised $1 million at a $10 million valuation, with the round set to close by the end of June. The founders, who self-funded early development, are now focused on bringing in strategic investors who can help scale B2B partnerships globally.
“We were surprised how easy it was to attract healthcare AI investment,” Lazuka admits. “Now the challenge is choosing the right investors – the ones who can really help us scale.”
Final word: Built for hope, not hype!
The BloodGPT team believes that trust is everything in healthcare.
“We’ve designed the system so that clinicians remain fully in control,” says Kron. “Everything is transparent, validated, and explainable – we want this to be a trusted clinical tool, not just another flashy AI.”
If anything, BloodGPT aims to be one step ahead of the hype cycle – combining the usability of ChatGPT with the rigour healthcare demands.
And with real users, real B2B pilots, and an already working product, this is one AI HealthTech story worth watching.
